AC
LKFT

Ascend Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Ascend Capital’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25,063
Closed -$2.5M – 195
2018
Q1 		$2.5M Buy
+25,063
New +$2.7M 0.1% 155
2017
Q3 		– Sell
-73,964
Closed -$5.66M – 178
2017
Q2 		$5.66M Buy
+73,964
New +$6.22M 0.26% 102

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ascend Capital's LKFT Position: Q2 2018 in Review

Ascend Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2018, closing a stake of 25,063 shares — an estimated $2.5M sold.

Ascend Capital first reported a position in LKFT in Q2 2017 and held it in 2 quarters. The position peaked at $5.66M in Q2 2017. 79 funds tracked by Wall St. Rank hold LKFT as of Q2 2018.

  • Ascend Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2018 after selling out during the quarter.
  • Ascend Capital sold 25,063 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2018, an estimated $2.5M.
  • Ascend Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2017 and held it in 2 quarters.
  • Ascend Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $5.66M in Q2 2017.
  • 79 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.